Licensing status

Publication and contact information


Breast cancer

Not applicable

Computational analysis of breast cancer samples from patients suggests therapeutic strategies used to treat ovarian cancer could help treat a class of basal-like breast tumors. Computational analysis of genomic and proteomic data from primary breast cancer samples identified basal-like breast tumors as a class with features similar to those of serous ovarian cancer. The data suggest patients with this class of breast tumors might benefit from treatment with poly(ADP-ribose)polymerase (PARP) inhibitors and/or platinum compounds used to treat serous ovarian cancer. Next steps could include clinical trials.
Abbott Laboratories has the PARP inhibitor veliparib in
Phase I and Phase II trials to treat multiple types of cancer.
AstraZeneca plc has the PARP inhibitor Olaparib in Phase I testing to treat brain cancer and Phase II trials to treat solid tumors.
BioMarin Pharmaceutical Inc. has BMN-673 in Phase I/II trials to treat hematologic malignancies and solid tumors.

SciBX 5(41); doi:10.1038/scibx.2012.1078
Published online Oct. 18, 2012

Unpatented; licensing status not applicable

The Cancer Genome Atlas Network. Nature; published online Sept. 23, 2012;
Contact: Charles M. Perou, The University of North Carolina at Chapel Hill, Chapel Hill, N.C.